BRAVO esophageal pH monitoring: more cost-effective than empiric medical therapy for suspected gastroesophageal reflux
| Autor: | Veronica Zoghbi, Rasa Zarnegar, Thomas J. Fahey, Thomas Ciecierega, Anna Aronova, David A. Kleiman, Brendan M. Finnerty, Cheguevara Afaneh, Carl V. Crawford |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male medicine.medical_specialty Esophageal pH Monitoring medicine.drug_class Cost-Benefit Analysis Proton-pump inhibitor Gastroenterology 03 medical and health sciences Young Adult 0302 clinical medicine Cost Savings Internal medicine medicine Humans Telemetry health care economics and organizations Aged medicine.diagnostic_test business.industry Reflux Hepatology Middle Aged medicine.disease Catheter Models Economic 030220 oncology & carcinogenesis GERD Gastroesophageal Reflux 030211 gastroenterology & hepatology Surgery Female Esophageal pH monitoring business Empiric therapy Wireless Technology Abdominal surgery |
| Zdroj: | Surgical endoscopy. 30(8) |
| ISSN: | 1432-2218 |
| Popis: | Early referral for catheter-based esophageal pH monitoring is more cost-effective than empiric proton-pump inhibitor (PPI) therapy to diagnose gastroesophageal reflux disease (GERD). We hypothesize that BRAVO wireless pH monitoring will also demonstrate substantial cost-savings compared to empiric PPI therapy, given its superior sensitivity and comfort. We reviewed 100 consecutive patients who underwent wireless pH monitoring for suspected GERD at our institution. A cost model and a cost equivalence calculation were generated. Cost-saving analyses were performed for both esophageal and extraesophageal symptoms. Eighty-seven patients were available for analysis. Median PPI use prior to referral was 215 weeks (range 0–520). Forty-three patients (49 %) had BRAVO results diagnosing GERD; 98 % of these had esophageal symptoms. Patients with negative BRAVO studies had a median of 113 (0–520) weeks of unnecessary PPI therapy. Cost-savings ranged from $1048 to $15,853 per patient, depending on sensitivity (75–95 %), PPI dosage, and brand. Maximum cost-savings occurred in patients with extraesophageal symptoms ($2948–$31,389 per patient). The PPI cost equivalence of BRAVO placement was 36 and 6 weeks for low- and high-dose therapy, respectively. BRAVO wireless pH testing is more cost-effective than prolonged empiric medical management for GERD and should be incorporated early in the treatment algorithm. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink